Trials / Completed
CompletedNCT03328494
Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies
A Phase 1/1b Study of Paclitaxel in Combination With BOS172722, a Monopolar Spindle 1 Kinase Inhibitor, in Patients With Advanced Nonhaematologic Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Boston Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will be conducted to assess the safety and tolerability of BOS172722 when administered as monotherapy and in combination with paclitaxel in participants with advanced nonhaematologic malignancies and also to establish the maximum tolerated dose and recommended Phase 2 dose of BOS172722 in combination with paclitaxel in those participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BOS172722 | Oral capsules |
| DRUG | Paclitaxel | IV infusion |
Timeline
- Start date
- 2017-10-13
- Primary completion
- 2021-03-16
- Completion
- 2021-03-16
- First posted
- 2017-11-01
- Last updated
- 2021-04-15
Locations
3 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03328494. Inclusion in this directory is not an endorsement.